Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

NCT01358084 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Pleural Mesothelioma

Interventions

DRUG: NGR-hTNF
DRUG: Placebo
OTHER: Best Supportive Care

Sponsor

AGC Biologics S.p.A.